Daiichi Sankyo and AstraZeneca Receive EU Approval for Datroway in First-Line Metastatic TNBC
TOKYO, July 31, 2026 Daiichi Sankyo and AstraZeneca announced that the European Commission (EC) has approved Datroway® (datopotamab deruxtecan)...
Daiichi Sankyo
Advertisement
Daiichi Sankyo and AstraZeneca Win CHMP Backing for Enhertu in HER2-Positive Breast Cancer
Tokyo, July 24, 2026 Daiichi Sankyo and AstraZeneca announced that the European Medicines Agency’s Committee for Medicinal Products for...
Daiichi Sankyo and AstraZeneca Secure EU Enhertu Approval
TOKYO, June 29, 2026 Daiichi Sankyo and AstraZeneca have announced that the European Commission (EC) has approved Enhertu® (trastuzumab...
AstraZeneca, Daiichi Sankyo Advance Datroway Toward EU Approval
CAMBRIDGE, UK & TOKYO, Japan, June 26, 2026 AstraZeneca and Daiichi Sankyo have moved one step closer to expanding...
AstraZeneca and Daiichi Sankyo Advance Enhertu in Tumour-Agnostic Oncology
Cambridge, United Kingdom – May 22, 2026 AstraZeneca and Daiichi Sankyo announced that the European Medicines Agency’s Committee for...
Advertisements
Datroway by AstraZeneca Approved as First TROP2 ADC for TNBC
Cambridge, United Kingdom – May 22, 2026 AstraZeneca and Daiichi Sankyo announced that the U.S. Food and Drug Administration...
Daiichi Sankyo Secures FDA Priority Review for ADC Therapy
Tokyo, Japan & Basking Ridge, New Jersey | April 13, 2026 Daiichi Sankyo, in collaboration with Merck & Co.,...
Imagene AI, Daiichi Sankyo Advance Oncology Biomarkers
Tel Aviv, Israel & Tokyo, Japan | April 9, 2026 Imagene AI has announced a strategic collaboration with Daiichi...
Tempus, Daiichi Sankyo Advance AI in ADC Oncology Trials
CHICAGO, Illinois, March 25, 2026 Tempus AI has announced a strategic collaboration with Daiichi Sankyo to accelerate AI-driven biomarker...
Daiichi Sankyo Expands ENHERTU Use in Japan
TOKYO, JAPAN, March 23, 2026 Daiichi Sankyo has announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has approved...
Advertisement
